Sequana Medical NV
Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid over… Read more
Sequana Medical NV (SEQUA) - Net Assets
Latest net assets as of June 2025: €-39.17 Million EUR
Based on the latest financial reports, Sequana Medical NV (SEQUA) has net assets worth €-39.17 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€14.57 Million) and total liabilities (€53.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-39.17 Million |
| % of Total Assets | -268.85% |
| Annual Growth Rate | N/A |
| 5-Year Change | -39456.34% |
| 10-Year Change | N/A |
| Growth Volatility | 329.61 |
Sequana Medical NV - Net Assets Trend (2014–2024)
This chart illustrates how Sequana Medical NV's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sequana Medical NV (2014–2024)
The table below shows the annual net assets of Sequana Medical NV from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-44.38 Million | -127.99% |
| 2023-12-31 | €-19.47 Million | -803.99% |
| 2022-12-31 | €-2.15 Million | -173.63% |
| 2021-12-31 | €-786.92K | -797.86% |
| 2020-12-31 | €112.76K | -87.82% |
| 2019-12-31 | €925.93K | +104.94% |
| 2018-12-31 | €-18.76 Million | -306.88% |
| 2017-12-31 | €-4.61 Million | +30.85% |
| 2016-12-31 | €-6.67 Million | -2242.31% |
| 2015-12-31 | €-284.66K | -109.99% |
| 2014-12-31 | €2.85 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sequana Medical NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20873151440.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €4.60 Million | % |
| Other Comprehensive Income | €849.00K | % |
| Other Components | €200.84 Million | % |
| Total Equity | €-44.38 Million | 100.00% |
Sequana Medical NV Competitors by Market Cap
The table below lists competitors of Sequana Medical NV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aspermont Ltd
AU:ASP
|
$14.42 Million |
|
Strategic Investments A/S
CO:STRINV
|
$14.42 Million |
|
Camimex Group JSC
VN:CMX
|
$14.42 Million |
|
Archtis Ltd
AU:AR9
|
$14.43 Million |
|
Mauch Chunk Trust Financial Corp
PINK:MCHT
|
$14.40 Million |
|
Singulus Technologies AG
XETRA:SNG
|
$14.40 Million |
|
Sejoong Co. Ltd
KQ:039310
|
$14.40 Million |
|
Lake Victoria Gold Ltd
OTCQB:LVGLF
|
$14.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sequana Medical NV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -19,465,174 to -44,379,000, a change of -24,913,826.
- Net loss of 44,654,000 reduced equity.
- New share issuances of 11,665,400 increased equity.
- Other comprehensive income increased equity by 2,862,931.
- Other factors increased equity by 5,211,843.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-44.65 Million | -100.62% |
| Share Issuances | €11.67 Million | +26.29% |
| Other Comprehensive Income | €2.86 Million | +6.45% |
| Other Changes | €5.21 Million | +11.74% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Sequana Medical NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | €-0.02 | €0.50 | x |
| 2016-12-31 | €-0.49 | €0.50 | x |
| 2017-12-31 | €-0.34 | €0.50 | x |
| 2018-12-31 | €-1.37 | €0.50 | x |
| 2019-12-31 | €0.08 | €0.50 | x |
| 2020-12-31 | €0.01 | €0.50 | x |
| 2021-12-31 | €-0.04 | €0.50 | x |
| 2022-12-31 | €-0.09 | €0.50 | x |
| 2023-12-31 | €-0.73 | €0.50 | x |
| 2024-12-31 | €-1.21 | €0.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sequana Medical NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -42126.42%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-1856.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | -685.89% | 0.36x | 0.00x | €-11.53 Million |
| 2016 | 0.00% | -938.67% | 0.39x | 0.00x | €-13.31 Million |
| 2017 | 0.00% | -630.78% | 0.37x | 0.00x | €-7.76 Million |
| 2018 | 0.00% | -1358.69% | 0.31x | 0.00x | €-12.11 Million |
| 2019 | -1617.55% | -1543.05% | 0.10x | 10.10x | €-15.07 Million |
| 2020 | -16943.83% | -1983.45% | 0.07x | 126.05x | €-19.12 Million |
| 2021 | 0.00% | -6373.84% | 0.03x | 0.00x | €-23.54 Million |
| 2022 | 0.00% | -3334.08% | 0.04x | 0.00x | €-30.55 Million |
| 2023 | 0.00% | -4572.42% | 0.07x | 0.00x | €-30.62 Million |
| 2024 | 0.00% | -42126.42% | 0.01x | 0.00x | €-40.22 Million |
Industry Comparison
This section compares Sequana Medical NV's net assets metrics with peer companies in the Medical Devices industry.
No peer company data available for comparison.